Value Added Abstracts - (2020) Volume 0, Issue 0
Published: 28-Aug-2020
Many schizophrenic patients, who are treated with antipsychotic drug, do not adhere to the pharmacotherpy. Antipsychotic drugs constitute a palliative treatment, and their long-term administration is not secure. Instead of following the pharmacotherapy, some patients tend to consume alcohol and tobacco, and even amphetamines and cannabis. The reason of the patients to not adhere to the pharmacotherapy will be discussed, and the effect of alcohol, tobacco and drugs on the disease outcome will be addressed. Appropriate measures to make the patients to renounce of substances and drugs and to improve the patients’ adherence to the pharmcotherapy will be described. Alterations of classical neurotransmitters in the hippocampus, mesolimbic system and prefrontal cortex will be mentioned. The different compounds of cannabis, tetrahydrocannabidiol (a psychotomimetic) and cannabidiol (exerts antipsychotic actions). The effect of alcohol, tobacco and drugs to worsen the antipsychotic treatment will be pointed out. Appropriate measures to improve the antipsychotic pharmacotherapy and to reduce the consumption of substances and drugs are the administration of long-acting injectable antipsychotic drugs and psychoeducation and cognitive behavioral therapy Some new drugs, for example the cannabis compound cannabidiol that shows antipsychotic properties and ß-varenicline, a nicotinergic cholinergic agonist, might be administered when substance abuse (cannabis, nicotine) occurs.
Biography:
Felix-Martin Werner studied human medicine at the University of Bonn. He has been working as a medical teacher in the formation of geriatric nurses, occupational therapists and assistents of the medical doctor at the Euro Academy in Pößneck since 1999. He has been doing scientific work at the Institute of Neurosciences of Castilla and León (INCYL) in Salamanca (Spain) since 2002. With Rafael Coveñas, he assisted at over 30 national and 12 international congresses of neurology and published over 40 reviews about neural networks in neurological and psychiatric diseases. Since 2014, he has been the member of the editorial board of the Journal of Cytology and Histology.
Speaker Publications:
1. “Classical neurotransmitters and neuropeptides involved in generalized epilepsy in a multi-neurotransmitter system: How to improve the antiepileptic effect? Epilepsy Behav. Volume 71, Part B, June 2017, Pages 124-129
2. “Neural networks in neurological and psychiatric diseases”; Current Pharmaceutical Design/ Volume 25, Issue 4, 2019, Pages 374-375
3. “Risperidone: A commentary on drug profiling”; Current Drug Discovery Technologies/ Volume 16, Issue 3, 2019, Pages 315-316.
4. “Comparison of mono-dopaminergic and multi-target pharmacotherapies in primary parkinson syndrome and assessment tools to evaluate motor and non-motor symptoms”; Current Drug Therapy/ Volume 14, Issue 2, 2019, Pages 124- 134
24th International Conference on Neurology & Neurophysiology; Berlin, Germany- March 16-17, 2020.
Abstract Citation:
Felix-Martin Werner, Therapeutic effect of novel antidepressant drugs interfering with receptors of neurotransmitters and neuropeptides, Neurophysiology 2020, 24th International Conference on Neurology & Neurophysiology; Berlin, Germany- March 16-17, 2020 (https://neurophysiology.neuroconferences.com/abstract/2020/influence-on-drug-and-substance-abuse-on-thedisease-outcome-in-schizophrenic-patients-treated-withantipsychotic-drugs)
Neurological Disorders received 1343 citations as per Google Scholar report
